Related Experiment Videos
[Treatment of HCV infection in HIV-positive patients]
M Puoti1, B Zanini, C Baiguera
1Clinica di Malattie Infettive e Tropicali, Università, e Azienda Ospedaliera Spedali Civili, Brescia. m.puoti@iol.it
Insights
Treating Hepatitis C virus (HCV) in HIV-positive individuals is crucial due to rising liver disease mortality and impacts on antiretroviral therapy. Interferon-based treatments show moderate success in viral suppression and eradication, but further research is needed.
Area of Science:
- Hepatology
- Virology
- Immunology
Context:
- Hepatitis C virus (HCV) infection is a growing concern for individuals with human immunodeficiency virus (HIV) co-infection.
- There is increasing mortality from advanced liver disease in this population.
- HCV infection negatively affects the efficacy and increases the toxicity of antiretroviral treatments for HIV.
Purpose:
- To evaluate the efficacy of interferon-based therapies for HCV in HIV-seropositive patients.
- To assess the impact of HCV treatment on HIV disease progression and antiretroviral therapy outcomes.
- To determine the clinical endpoints of HCV eradication or viral suppression in co-infected patients.
Summary:
- Interferon monotherapy achieved HCV eradication in 17% and viral suppression in 26% of treated HIV-infected subjects.
- Combination therapy with interferon and ribavirin resulted in HCV eradication in 28% and viral suppression in 36% of patients.
- Further studies are required to establish the impact of these treatments on HIV disease progression, antiretroviral efficacy, toxicity, and compliance.
Impact:
- HCV treatment can slow liver disease progression and reduce hepatotoxicity associated with antiretroviral drugs.
- Understanding treatment outcomes is vital for managing co-infected patients and optimizing HIV care.
- The cost-effectiveness of anti-HCV therapy in HIV-infected individuals remains to be defined.
Abstract:
Treatment of HCV infection in HIV seropositives is becoming a management priority because of: the increasing HCV and stage liver disease mortality and the unfavourable impact of HCV infection on efficacy and toxicity of antiretroviral combination treatment. Treatment end points are: eradication of HCV or suppression of HCV replication in order to slow HCV disease progression and to increase efficacy and to reduce hepatotoxicity of antiretrovirals. Interferon as monotherapy and in combination with ribavirin induces eradication of HCV in respectively 17 and 28% and suppression of viral replication in 26 and 36% of treated HIV infected subjects. The impact of these drugs on HIV disease evolution and on antiretroviral treatment efficacy, toxicity and compliance needs to be established. Then the cost-effectiveness of anti HCV therapy in anti HIV infected patients still needs to be defined.